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Abstract
 
Eosinophil accumulation is a distinctive feature of lung al-
lergic inflammation. Here, we have used a mouse model of
OVA (ovalbumin)-induced pulmonary eosinophilia to study
the cellular and molecular mechanisms for this selective re-
cruitment of eosinophils to the airways. In this model there
was an early accumulation of infiltrating monocytes/mac-
rophages in the lung during the OVA treatment, whereas
the increase in infiltrating T-lymphocytes paralleled the ac-
cumulation of eosinophils. The kinetics of accumulation of
these three leukocyte subtypes correlated with the levels of
mRNA expression of the chemokines monocyte chemotactic
peptide-1/JE, eotaxin, and RANTES (regulated upon acti-
vation in normal T cells expressed and secreted), suggesting
their involvement in the recruitment of these leukocytes.
Furthermore, blockade of eotaxin with specific antibodies in
vivo reduced the accumulation of eosinophils in the lung in
response to OVA by half. Mature CD4
 
1
 
 T-lymphocytes
were absolutely required for OVA-induced eosinophil accu-
mulation since lung eosinophilia was prevented in CD4
 
1
 
-
deficient mice. However, these cells were neither the main
producers of the major eosinophilic chemokines eotaxin,
RANTES, or MIP-1
 
a
 
, nor did they regulate the expression
of these chemokines. Rather, the presence of CD4
 
1
 
 T cells
was necessary for enhancement of VCAM-1 (vascular cell
adhesion molecule-1) expression in the lung during allergic
inflammation induced by the OVA treatment. In support of
this, mice genetically deficient for VCAM-1 and intercellu-
lar adhesion molecule-1 failed to develop pulmonary eosi-
nophilia. Selective eosinophilic recruitment during lung al-
lergic inflammation results from a sequential accumulation
of certain leukocyte types, particularly T cells, and relies on
the presence of both eosinophilic chemoattractants and ad-
hesion receptors. (
 
J. Clin. Invest. 
 
1996. 98:2332–2345.) Key
words: lung eosinophilia 
 
• 
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• 
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Introduction
 
Lung eosinophilia is a fundamental trait of allergic asthma and
infiltration of the airways by eosinophils appears to be central
in the pathogenesis of this disease (1–3). The traffic of eosino-
phils to the sites of allergic reactions is presumed to be regu-
lated at three distinct levels: (
 
a
 
) adhesion receptors (selectins
and integrins) that mediate transient or firm adhesion to in-
flamed vascular endothelium; (
 
b
 
) activating factors (cytokines,
chemokines, and chemoattractants) that induce expression of
selectins and their ligands, and that activate eosinophil inte-
grins and their endothelial counter-receptors, thus attracting
this leukocyte subtype to the inflammatory site; and (
 
c
 
) leuko-
cytes that are present at the inflammation site and which regu-
late the expression and release of these activating factors (4–9).
Despite the fact that most molecules or cells involved at any of
these three regulation levels are not eosinophil specific, they
can provide sufficient combinatorial diversity to allow selec-
tive recruitment of eosinophils to the lung in vivo (6, 10).
Eosinophils express several adhesion receptors such as 
 
b
 
1
and 
 
b
 
2 integrins, E-selectin and P-selectin ligands (11), and
L-selectin (11, 12). These surface molecules enable them to in-
teract with the vascular endothelium. Eosinophil transendo-
thelial migration in vitro can be partially inhibited by blocking
the interactions of lymphocyte function-associated antigen 1
(LFA-1)
 
1
 
 and very late activation antigen 4 (VLA-4) with in-
tercellular adhesion molecule 1 (ICAM-1), and vascular cell
adhesion molecule 1 (VCAM-1) on endothelial cells, respec-
tively (4, 5, 13, 14). Inhibition of this transmigration can be in-
creased by blocking with an anti–E-selectin mAb (15). Recent
in vivo experiments document that antigen-induced eosinophil
infiltration of the mouse trachea is prevented by blocking
VCAM-1–VLA-4, but not ICAM-1–LFA-1 interactions (16).
In contrast, the in vivo administration of an anti–ICAM-1
mAb leads to decreased eosinophil infiltration and attenuated
airway hyperreactivity in a primate model of chronic airway in-
flammation (17).
Chemoattractants, such as platelet activating factor and
leukotriene B4, and several human chemokines, including
monocyte chemotactic peptide 3 (MCP-3), macrophage in-
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Abbreviations used in this paper:
 
 BAL, bronchoalveolar lavage;
ICAM-1, intercellular adhesion molecule-1; LFA-1, lymphocyte func-
tion-associated antigen 1; MCP, monocyte chemotactic peptide; MIP,
macrophage inflammatory protein; OVA, ovalbumin; RANTES, reg-
ulated upon activation in normal T cells expressed and secreted;
VCAM-1, vascular cell adhesion molecule-1; VLA-4, very late activa-
tion antigen 4; wt, wild-type.
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flammatory protein 1
 
a
 
 (MIP-1
 
a
 
), and regulated upon activa-
tion in normal T cells expressed and secreted (RANTES) have
been reported to elicit significant migration of eosinophils (11,
18, 19). Recently, eotaxin, a chemokine that is highly efficient
in inducing migration of eosinophils, has been identified and
extensively studied in guinea pigs (20, 21), mice (22, 23), and
humans (24).
Pathological processes that result in lung eosinophilia may
involve antigen-induced T cell activation through macrophages
or other antigen presenting cells, T cell cytokine release, spe-
cific sensitization of mast cells, and release of activating media-
tors by macrophages (8). Macrophages are able to amplify the
inflammatory response and to increase eosinophil prolifera-
tion and survival by virtue of their potential to generate a vari-
ety of proinflammatory mediators and cytokines (25–28).
There is a strong correlation between the level of cytokines
released by activated T cells and the degree of eosinophil-
mediated tissue damage in the lung (29, 30). Eosinophils and
lymphocytes tend to appear in certain types of inflammatory
lesions in the absence of a marked neutrophilic infiltration
(31, 32). Indeed, the accumulation of eosinophils at sites of al-
lergic reactions has been directly correlated with the produc-
tion of T cell cytokines such as IL-5, IL-3, and GM-CSF, which
are known to stimulate eosinophil maturation, activation, and
survival (33–36) and IL-4, which enhances the endothelial ex-
pression of VCAM-1 (37–40). VCAM-1 upregulation may
augment the migration of eosinophils but not of neutrophils,
which lack VLA-4 (14).
Selective activation of adhesion molecules on eosinophils
and endothelial cells by leukocyte cytokines (IL-4, IL-1
 
b
 
,
TNF-
 
a
 
) (15, 39, 41) and production of eosinophilic chemo-
kines (RANTES, eotaxin) by different cell types (23, 42) could
promote eosinophil migration and their subsequent accumula-
tion in the tissue. Cooperation between these groups of media-
tors has been demonstrated during in vivo recruitment of eosi-
nophils (43).
The molecular cloning and functional characterization of
the leukocyte integrins, their endothelial Ig gene superfamily
ligands, and of selectins has made it possible to construct mu-
tant mice to address the roles of these molecules in different
pathological situations in vivo (44, 45). This, together with the
identification and cloning of specific chemokines, facilitates
the determination of the molecular and cellular basis of migra-
tion of different leukocytes and its regulation during inflam-
mation. Here, using a mouse model of lung eosinophilia in
vivo based on the repeated exposure of mice to aerosolized
ovalbumin (OVA) (23), we analyze (
 
a
 
) the kinetics of accumu-
lation in the lung of several leukocyte subtypes during the
OVA treatment; (
 
b
 
) the correlation between the accumulation
of specific leukocyte subtypes and the expression of several
chemokines (RANTES, eotaxin, MCP-1/JE, MIP-1
 
a
 
, and TCA-3)
in eosinophilic lungs; (
 
c
 
) the effects of the blockade of eotaxin
in vivo on the kinetics of accumulation of eosinophils; (
 
d
 
) the
specific role of B–, CD4
 
1
 
– and CD8
 
1
 
–T-lymphocytes during
lung eosinophilia by studying the response to the OVA treat-
ment in mice lacking these leukocyte subtypes; (
 
e
 
) changes in
the expression of these chemokines and adhesion receptors in
the absence of these lymphocyte subtypes during lung eosino-
philia in vivo; and (
 
f
 
) the contribution of the individual adhe-
sion receptors ICAM-1, VCAM-1, P-selectin, and L-selectin to
the eosinophil accumulation in this model by using mice that
have been made genetically deficient in these molecules.
 
Methods
 
Mice and in vivo procedures. 
 
8–10-wk-old male and female C57BL/
6J, RAG-1, and P-selectin–deficient mice were purchased from the
Jackson Laboratory (Bar Harbor, ME) and kept in the Center for
Blood Research Specific Pathogen Free mouse facility. CD4- and
CD8-deficient mice (46, 47) were provided by Dr. Tak W. Mak (AM-
GEN Institute, Toronto, Canada), and CD3
 
e
 
 transgenic mice (48)
were kindly provided by Dr. C. Terhorst (Beth Israel Hospital, Bos-
ton, MA). L-selectin–deficient mice were generated and provided by
Dr. M. Siegelman. Since VCAM-1–null mutant mice are embryonic
lethal (49), VCAM-1–hypomorphic mutant mice were used for these
studies (50). These mutant mice were generated by a targeted dele-
tion in domain 4 of the VCAM-1 molecule (which eliminates the
main 
 
a
 
4 integrin binding site). The mRNA level of the truncated
VCAM-1 molecule in the hypomorphic mutants used here is 95% re-
duced compared to wild type (wt) levels (50 and not shown). Also,
the affinity of the remaining truncated VCAM-1 to 
 
a
 
4 integrins is
presumably greatly diminished as shown previously in vitro (51).
ICAM-1–deficient mice were previously generated by us (52). Mice
designated as wt in the results section are littermates of these mutants
that have a mixed genetic background 129sv 
 
3
 
 C57BL/6J. Pulmonary
eosinophilia in response to OVA (Sigma Chemical Co., St. Louis,
MO) was generated in these groups of mice as described (23). The
murine model of lung eosinophilia used here consists of an initial
phase of sensitization and a second phase of induction of the re-
sponse. Thus, mice were sensitized with intraperitoneal OVA (0.1
mg/mouse) on day 1 followed by exposure to aerosolized antigen (2%
OVA for 5 min on day 8 and 1% OVA for 20 min on days 15–21) to
induce the response. At different times after allergen challenge, ani-
mals were killed by barbiturate overdose and analyzed. PBS (intra-
peritoneal and aerosolized) was administered to mice as a negative
control. The following number of mice of the indicated strains were
used per time point in three individual experiments: 10, 4, and 4
C57BL/6J mice per time point for experiments shown in Figs. 1, 4 
 
A
 
,
and 6, respectively; 4 RAG-1, CD4 and CD8-deficient mice, and 4
CD3
 
e
 
 transgenic mice per time point for experiments shown in Fig. 4
 
A
 
; 4 ICAM-1, VCAM-1, and P-selectin–mutant mice and 3 L-selec-
tin–mutant mice per time point for experiments shown in Fig. 6. In
one series of blocking experiments, mice were injected with neutraliz-
ing polyclonal Abs against murine eotaxin (20 
 
m
 
g/mouse, i.v.) 30 min
before OVA administration on days 20 and 21 and then analyzed 3 h
after allergen challenge on day 21. OVA-treated control mice were
injected with the same amount of control Ab (rabbit immunoglobulin
fraction; Dako Corp., Santa Barbara, CA) at the same time points in-
dicated during treatment. No endotoxin contamination was detected
in all reagents used, as assessed by LAL assay (BioWhittaker, Walk-
ersville, MD).
Bronchoalveolar lavage (BAL) was essentially performed as de-
scribed (23). Briefly, at the different time points indicated after the
last aerosol exposure, the airways of the mice were lavaged via a tra-
cheal cannula with 1 ml of PBS. The resulting BAL fluid was immedi-
ately centrifugated (700 
 
g
 
, 5 min, 4
 
8
 
C) and BAL cells were then
washed twice and resuspended in 1 ml of PBS.
 
Immunohistochemical phenotyping and quantitation of leukocytes.
 
The number and type of leukocytes were determined in lung sections
and BAL fluid. Excised lungs from OVA-treated mice were obtained
at the indicated time points, fixed in 10% formalin, embedded in par-
affin (Tissue-Tek, Miles Inc., Somerset, MA), and sectioned at 5 
 
m
 
m
on a microtome (Reichert-Jung, Vienna). To determine the number
of eosinophils, a sensitive method dependent on the presence of a cy-
anide-resistant endogenous peroxidase was used (23).
To determine the number of lymphocytes, macrophages, and neu-
trophils and to analyze the expression of ICAM-1 and VCAM-1 pro-
tein, remaining portions of the excised lungs were rolled in Tissue
Tek OCT compound (Cryoform, IEC, Needham Heights, MA), snap
frozen in liquid nitrogen and stored at 
 
2
 
70
 
8
 
C. Cryosections (4 
 
m
 
m)
were cut onto microscope slides, dried for 2 h, and fixed for 20 min in
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acetone at 4
 
8
 
C. Fixed sections were stained with mAb directed
against Thy 1.2 (53–2.1), Mac-1 (M1/70), GR.1 (RB6-8C5), and IgM
(II/41) from PharMingen (San Diego, CA) and ICAM-1 (YN1/1.7.4)
and VCAM-1 (mK2.2) kindly provided by Drs. Springer and Lobb,
respectively, using an avidin/biotin staining method. All incubations
were carried out under humidified conditions and slides were washed
between steps (twice for 5 min each in 0.1 M phosphate buffered sa-
line, pH 7.4). Sections were overlaid with 20% fetal calf serum in PBS
for 15 min and incubated for 1 h at room temperature with the mAbs
described above. Bound ab was visualized by incubation with biotiny-
lated sheep anti–rat immunoglobulin (Dako Corp.) and then with
streptavidin peroxidase complex (Dako Corp.) both diluted in 1%
normal mouse serum/PBS (NMS/PBS), and incubated for 30 min. Fi-
nally slides were flooded with peroxidase substrate solution (400 mg
diaminobenzidine in 10 ml of PBS, containing 0.01% hydrogen per-
oxide) for 10 min. Control sections were included where mAb, bioti-
nylated anti–rat immunoglobulin or streptavidin complex were selec-
tively omitted.
Number of leukocyte subtypes was determined in four high
power fields (at a magnification of 40; total area 0.5 mm
 
2
 
) per section
(duplicate sections per mouse and time point were examined). These
high power fields were selected randomly under a low power of mag-
nification (
 
3
 
4) at which leukocyte subtypes were not visible and com-
pared with the number of leukocytes present in control mice.
To determine the number and type of leukocytes in the BAL
fluid, samples were applied to glass slides by cytocentrifugation (5 
 
3
 
 10
 
5
 
cells/slide), air dried for 10 min and then immersed in Wright-Giemsa
stain (Fisher Diagnostics, Pittsburgh, PA), rinsed with distilled water,
air dried, and mounted. Percentage of eosinophils, lymphocytes, neu-
trophils, and macrophages was determined by counting their number
in eight high power fields (at a magnification of 40; total area 0.5
mm
 
2
 
) per area selected by the same criteria as above and dividing this
number by the total number of cells per high power field. To obtain
the absolute number of each leukocyte subtype in the lavage, these
percentages were multiplied by the total number of cells recovered
from the BAL fluid.
 
Measurement of mRNA expression by Northern blots. 
 
Total RNA
from eosinophilic lungs of OVA-sensitized wt mice (1, 3, and 6 h after
treatment on days 15, 18, and 21) and from lungs of OVA-treated
mutant mice (3 h after challenge on days 15, 18, and 21) was isolated
using the guanidinium thiocyanate/acid phenol procedure (53). RNA
from lungs of PBS-treated mice at the same time points was used as a
control. Northern blots (54) were performed with 20 
 
m
 
g of total RNA
indicated above, fractionated in a 1.5% agarose/formaldehyde gel,
and blotted onto a nylon membrane (Genescreen; DuPont, Willming-
ton, DE). Membranes were probed using 
 
32
 
P-labeled mouse probes
for eotaxin (23), RANTES (55), MCP-1/JE (56), MIP-1
 
a
 
 (57), and
TCA-3 (58) applied in 50% formamide hybridization solution at 42
 
8
 
C
for 18 h. Blots were washed in 2 
 
3
 
 SSC/1% SDS at 45
 
8
 
C and exposed
at 
 
2
 
70
 
8
 
C on Kodak XAR5 film.
 
Anti-eotaxin antibody generation. 
 
Polyclonal Abs against murine
eotaxin were prepared according to standard methods (59). Briefly,
100 
 
m
 
g of purified recombinant eotaxin (23) were inoculated into rab-
bits together with complete Freund’s adjuvant and challenged at dif-
ferent time points after immunization. Ab titers were determined in
an ELISA using recombinant meotaxin as immobilized antigen. Rab-
bit serum was first depleted of antihuman IgG Abs by passage over a
human IgG column and anti-meotaxin Abs were purified from the
flow through on a meotaxin affinity column. Bound Ab were eluted
with 0.1 mol/liter acetic acid/0.12 mol/liter NaCl (pH, 3.0), immedi-
ately neutralized with 1 mol/liter Tris (pH, 8.8), dialyzed against three
changes of PBS, and stored at 
 
2
 
70
 
8
 
C in 10% glycerol/PBS.
For production of mAbs against eotaxin 10-wk-old Wistar rats
were immunized in the hind footpad with KLH-coupled recombinant
eotaxin using a standard protocol used by us previously (60). 8 d after
immunization popliteal lymph nodes were removed and fused with
the murine plasmacytoma P3X63Ag8.653 (60). 12 d after fusion,
supernatants from growing wells were screened by ELISA for the
presence of anti-eotaxin Abs. Positive supernatants were studied in
Western blot analysis against eotaxin produced by transfected cells.
Positive hybridomas were stabilized by limiting dilution using BALB/c
mouse thymocytes as a feeder layer until stable Ab production was
achieved.
Affinity purified rabbit polyclonal Abs and rat mAbs were shown
to recognize a specific band in a Western blot against eotaxin-con-
taining supernatant but not against the supernatant of mock-trans-
fected cells (data not shown).
 
Determination of eotaxin protein expression within lung tissue.
 
The level of expression of eotaxin protein was determined in sections
from lungs of OVA-treated mice and controls. Sections were pre-
pared as detailed above and staining was accomplished using a modi-
fied avidin/biotin staining method. All incubations were carried out
under humidified conditions and slides were washed twice between
steps for 5 min each in 0.1 M PBS supplemented with 0.2% gelatin
(PBSG). Sections were overlaid with 20% normal rabbit serum in
PBS for 15 min and then incubated overnight at 4
 
8
 
C with monoclonal
anti-eotaxin diluted 1:2 in PBS with 0.1% BSA and 0.1% sodium
azide. Endogenous peroxide was subsequently blocked by incubation
for 20 min in methanol containing 0.3% hydrogen peroxide. Non-spe-
cific staining due to cross reaction with endogenous avidin or biotin
was blocked by incubation with avidin solution followed by biotin so-
lution, both for 20 min. Bound monoclonal Ab was visualized by in-
cubation with biotinylated rabbit anti–rat immunoglobulin diluted in
10% normal mouse serum PBS, and then streptavidin peroxidase
complex prepared according to manufacturer’s instructions (both
from Dako Corp.), and incubated for 1 h each. Finally, slides were
flooded with peroxidase substrate solution (20 mg diaminobenzidine
in 10 ml PBS, containing 0.01% hydrogen peroxide) for 10 min before
counter staining with hematoxylin. Control slides were either stained
with an irrelevant Ab (anti-TR5) (61) or biotinylated anti–rat immu-
noglobulin or streptavidin complex were selectively omitted.
 
Results
 
Characterization of leukocyte accumulation in the mouse lung
in response to OVA. 
 
To characterize leukocyte types recruited
to lung airways and parenchyma after antigen challenge, as
well as their time of arrival to this organ, preimmunized mice
(day 1) were challenged with repeated aerosolized exposure to
OVA (days 8 and 15–21). At different time points (0, 1, 3, 6,
and 12 h) after exposure to OVA on days 15, 18, and 21 of
treatment, leukocytes present in the BAL fluid and in the lung
parenchyma were ennumerated (Fig. 1). Analysis of the pul-
monary infiltration at these two levels (in the airways by BAL
or in the parenchyma by counting leukocytes in the tissue)
demonstrated a marked increase in the total number of leuko-
cytes present in this tissue. We have previously characterized
the kinetics of lung eosinophil accumulation in this model (23).
Briefly, a progressive increase in the number of eosinophils is
detected in lung tissue and BAL, reaching a maximum level at
day 21 of treatment. Each day after OVA administration there
is a transient increase in BAL and tissue eosinophils which is
maximal at 3 h. Kinetics of eosinophil infiltration are shown in
the bottom of Fig. 1 for comparison with the other leukocyte
subtypes. Lymphocyte accumulation in BAL and lung tissue
follows a similar profile to that of eosinophils, in that within
6–12 h after OVA challenge on day 15, we detected a fivefold
increase in the number of T-lymphocytes in lung tissue (Fig. 1).
On days 18 and 21 of OVA treatment, a progressive increase
in tissue infiltrating T-lymphocytes was evident. This increase
peaks at 3 h at both time points and constitutes 20- and 25-fold
for T-lymphocytes on days 18 and 21, respectively, and is
readily detectable within 1 h after the OVA inhalation. The
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number of lymphocytes present in the BAL fluid also in-
creases during the course of this treatment and becomes maxi-
mal 3 h after OVA administration on day 21 (15-fold increase;
Fig. 1). It should be noted that 12 h after OVA administration,
the number of total lymphocytes in BAL fluid decreases to al-
most basal levels while tissue infiltrates (perivascular and peri-
bronchiolar) remain well above basal levels in the lung (as was
observed for eosinophils).
The kinetics of macrophage accumulation in the lung dur-
ing the response to OVA is inverse to that described above for
eosinophils and lymphocytes. Macrophage accumulation peaks
3 h after OVA administration on day 15 by 3–4-fold in lung tis-
sue and by 50-fold in BAL fluid (Fig. 1). Increased numbers of
macrophages were also observed in both lung tissue and BAL
fluid on days 18 and 21 although to a lesser degree than on day
15. At all time points examined the number of infiltrating mac-
rophages decreases almost to basal levels by 12 h after last
OVA administration.
No significant and persistant increase in neutrophil, B-lym-
phocyte, and mast cell numbers was detected during the course
of this treatment when OVA and control mice were compared
(data not shown).
 
Chemokine expression during the development of OVA-
induced lung eosinophilia. 
 
Since chemokines are important
inflammatory mediators involved in the recruitment and acti-
vation of leukocytes at sites of inflammation, we tried to corre-
late OVA-induced eosinophil, T-lymphocyte, and macrophage
accumulation with the expression of chemokines specific for
these cell subtypes. We assessed the expression of mRNA for
murine RANTES (CD4
 
1
 
 T cell and eosinophil chemoattrac-
tant) (62), MCP-1/JE, (macrophage chemoattractant) (63),
MIP-1
 
a
 
 (monocyte and eosinophil chemoattractant) (64, 65),
TCA-3 (neutrophil and monocyte chemoattractant) (66), and
eotaxin (eosinophil chemoattractant) (23) during lung eosino-
philia. Northern blots of total RNA isolated from lungs of
OVA-treated mice on days 15, 18, and 21 (1, 3, and 6 h after
OVA inhalation) revealed a comparable pattern of RANTES
and eotaxin mRNA expression (Fig. 2 
 
A
 
). Induction of MCP-
1/JE mRNA in response to OVA challenge was maximal at 3 h
after OVA-administration on day 15 of treatment. On the
same day, 6 h after antigen challenge significant MCP-1/JE
mRNA expression was still detectable. On days 18 and 21,
Northern blot analyses revealed a transient increase in MCP-1/
JE mRNA expression detected 3 h after OVA administration
(Fig. 2 
 
A
 
). The mRNA expression of TCA-3 was virtually un-
detectable during the course of this treatment and there was
no discernible increase at any time point after OVA challenge
(Fig. 2 
 
A
 
). Finally, the pattern of mRNA expression for
MIP-1
 
a
 
 was not distinguishable from that described above for
RANTES or eotaxin (Fig. 2 
 
A
 
).
Among the chemokines examined above, eotaxin is the
most selective regarding the chemoattraction of eosinophils
(20, 67). In addition, its transcription profile correlates well
with the accumulation of eosinophils in vivo. To determine the
predominant cell type(s) producing eotaxin in this model and
the relevance of eotaxin expression in the accumulation of
eosinophils in vivo, we generated Abs against eotaxin. The
Figure 1. Pulmonary accumulation of lymphocytes and monocytes/
macrophages in response to OVA treatment. Lymphocyte and mac-
rophage infiltration in lung sections (dots) and BAL fluid (bars) are 
shown on days 15, 18, and 21 of OVA treatment at the different time 
points indicated. The treatment is described in detail in the Methods 
section. Solid circles and open circles represent the numbers of the in-
dicated cell types counted in lung sections of experimental and con-
trol mice, respectively. The kinetics of eosinophil accumulation at the 
same time points is shown for comparison in the figure. Error bars in-
dicate the standard deviation of the average of each cell type counted 
in four high power fields per lung in 3 individual experiments with 10 
OVA-treated mice per time point and experiment. Total number of 
eosinophils, lymphocytes, and monocytes/macrophages in the BAL 
fluid was calculated as the product of the total cellularity of the BAL 
and the percentage of each cell type. Each value was corrected for 
background by subtracting values of control mice from OVA-treated 
littermates.
 
Table I. Properties of a Panel of Anti-meotaxin mAbs
 
mAb ELISA Western blot
Staining
lung sections*
Neutralizing
activity
 
‡
 
mEOT-1
 
1 11 11
 
ND
mEOT-2
 
1 11 11
 
ND
mEOT-3
 
1 1 2
 
ND
mEOT-4
 
1 2 2
 
ND
mEOT-5
 
1 11 11
 
ND
mEOT-6
 
1 11 11
 
ND
mEOT-7
 
1 11 11
 
ND
mEOT-8
 
1 1 2
 
ND
mEOT-9
 
1 1 2
 
ND
polyEOT
 
1 11
 
ND
 
1
 
*Immunohistochemical staining was performed as described in Methods
using lungs from OVA-treated mice. 
 
‡
 
Neutralizing activity of the anti-
eotaxin polyclonal antibody was assessed previously in vitro by transmi-
gration experiments (97% blocking). (
 
11
 
 and 
 
1
 
) Strong and weak re-
activity in Western blots and immunohistochemistry. (
 
2
 
) No staining.
(ND) Not determined.
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properties of nine selected mAbs and one polyclonal Ab are
outlined in Table I. All these Abs were determined to be spe-
cific for eotaxin by ELISA. Five of the eotaxin specific mAbs
showed strong reactivity in Western blots and were able to rec-
ognize an epitope of mouse eotaxin that is preserved in frozen
sections of lung. The anti-eotaxin polyclonal Ab was noted for
its ability to block the in vitro transmigration of eosinophil to
eotaxin by 97% (Table I and data not shown). Neutralizing
properties of mAbs are currently being investigated. Immuno-
histochemical analysis of eotaxin protein expression in sections
of eosinophilic lungs from OVA-treated mice was performed.
Our results show that most of the eotaxin protein expressed
Figure 2. Chemokine expression during lung eosinophilia. (A) Expres-
sion of eotaxin, RANTES, MIP-1a, MCP-1/JE, and TCA-3 mRNAs in 
the lung during OVA treatment. On days 15, 18, and 21, total RNA 
from lungs of OVA-treated mice was extracted 1, 3, and 6 h after anti-
gen administration. In a control group, mice were treated with aero-
solized PBS instead of OVA. Eotaxin, RANTES, MCP-1/JE, MIP-1a, 
and TCA-3 mRNA induction was determined by Northern blot. 
Chemokine expression of one representative mouse out of four is 
showed. Lower panel shows a control hybridization of the blot with a 
b-actin probe. (B) Immunohistochemical staining of lung sections 
from OVA-treated mice on day 21, 3 h after OVA inhalation (I, II, 
and IV) and a PBS control (III). Sections were stained with anti-
eotaxin mAb (mEOT-1) (see Methods) (II, III, and IV) or a negative 
control isotype matched mAb (I). Note that positive staining, seen as a 
brown precipitate, is not detected in infiltrating cells (arrowheads) but 
is observed in resident lung cells, in particular the alveolar endothe-
lium (arrows). 31,000.
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can be attributed to resident lung cells (Fig. 2 
 
B
 
). In particular,
increased expression was observed in alveolar epithelial cells
after OVA treatment confirming our previous data obtained
by in situ hybridization (23). Few, if any, of the leukocytes that
constitute perivascular infiltrates (mainly eosinophils and lym-
phocytes) showed positive staining at late stages of OVA-
induced eosinophilia (Fig. 2 
 
B
 
).
To determine the particular contribution of eotaxin to the
development of OVA-induced lung eosinophilia, blocking
experiments in vivo with anti-eotaxin polyclonal Abs were
performed. Intravenous administration of anti-eotaxin Abs re-
sulted in a 56% reduction of eosinophils in BAL when com-
pared with OVA-treated control mice (Fig. 3).
 
Role of lymphocytes in pulmonary eosinophilia: response of
mice with selective immunodeficiencies to OVA. 
 
In the light
of the distinct kinetics of lymphocyte and macrophage accu-
mulation in this model and, particularly of the parallel kinetics
of eosinophil and lymphocyte accumulation, we evaluated the
contribution of these cell types to the induction of eosinophilia
in vivo. To dissect the specific role that different lymphocyte
subtypes may play in the accumulation of eosinophils in this
model, we studied the response of RAG-1–deficient mice (T
and B cell–deficient) (68) and CD3
 
e
 
 transgenic mice (T and
NK cell–deficient)(48), as well as mice lacking either CD4
 
1
 
 or
CD8
 
1
 
 T-lymphocytes (46, 47) to the OVA treatment. 3 h after
OVA challenge on day 21, BAL fluid from these immunodefi-
 
cient mice was obtained and leukocyte subtypes were enumer-
ated. Fig. 4 
 
A
 
 shows that there is almost a complete reduction
in the number of infiltrating eosinophils recovered from the
BAL fluid of OVA-treated RAG-1–deficient mice and CD3e
transgenic mice when compared with OVA-treated wt litter-
mates. We observed a small but detectable population of lym-
phocytes (1/20 of that found in wt mice) in the BAL fluid of
CD3e transgenic mice at the same time point analyzed (Fig. 4
A). To further investigate whether CD41 and/or CD81 T-lym-
phocytes are both required for the induction of eosinophilia in
this model, mice lacking either CD41 or CD81 T-lymphocytes
were also examined (Fig. 4 A). We observed a comparable re-
duction of eosinophils in the BAL of CD4-deficient mice to
that found in RAG-1–deficient mice or CD3e transgenic mice.
In contrast, CD8-deficient mice subjected to the same treat-
ment showed no significant changes in BAL eosinophilia when
compared to OVA-treated wt littermates (Fig. 4 A). In addi-
tion, a similar degree of lymphocyte infiltration was found in
wt and CD8-deficient mice (Fig. 4 A) suggesting that a signifi-
cant fraction of the infiltrating lymphocytes belong to the
CD41 lineage (z70%, as shown by the numbers of lympho-
cytes in CD4-deficient mice, Fig. 4 A). The number of mac-
rophages (Fig. 4 A) and neutrophils (data not shown) recov-
ered from the BAL fluid of these mutant mice remained
comparable to their corresponding wt littermates at this time
point of the OVA treatment. Similarly, maximal macrophage
accumulation occurred on day 15 in both groups of mice (data
not shown).
To exclude the chance that cells might have migrated into
the interstitium but not progressed into the airways in the ab-
sence of CD41 T cells, lung sections from OVA-treated RAG-1,
and CD4-deficient mice (3 h after OVA challenge on day 21)
were prepared and the number of eosinophils in the paren-
chyma was counted. No eosinophil infiltration was detected in
the lungs of these mutant mice when compared with wt or
CD8-mutant mice (data not shown and Figs. 4 C, and 5).
To rule out the possibility that pulmonary eosinophil accu-
mulation in response to OVA was delayed rather than abro-
gated in RAG-1 and CD4-deficient mice, BAL fluid obtained
7 h after OVA administration on day 21 was analyzed. As was
detected at the 3 h time point, no eosinophil infiltration was
seen at this later time point in these mutants (data not shown).
Wt and CD8-mutant mice showed similar numbers of infiltrat-
ing eosinophils at this time point (data not shown). To exclude
the possibility that prevention of lung eosinophilia after expo-
sure to OVA in these mutant mice was due to impaired bone
marrow eosinophil differentiation resulting from an intrinsic
lack of IL-5–producing CD41 T cells, IL-5 was intravenously
administered and 1 h later, numbers of eosinophil recovered
from the blood of the different IL-5–treated mutant mice were
determined. No differences were detected in the number of
circulating eosinophils shortly after IL-5 injection in mutant
mice that did not develop OVA-induced BAL eosinophilia
(i.e., CD4 or RAG-1-mutant mice) when compared with those
found in wt and CD8-deficient mice (data not shown). To ex-
clude the possibility that functional differentiation of eosino-
phils was affected in CD4-deficient mice, IL-5 was adminis-
tered both intravenously and intraperitoneally daily over 1 wk.
2 h after the final IL-5 injection, eosinophil accumulation into
the peritoneum of these treated CD4-deficient mice was evalu-
ated. Peritoneal eosinophilia was not impaired in these mutant
mice when compared with wt littermates (data not shown).
Figure 3. In vitro blockade of eotaxin with specific neutralizing Abs 
during OVA-induced eosinophilia. 30 min before antigen challenge 
on the last two days of OVA treatment, mice were injected with neu-
tralizing Abs against eotaxin as described in the Methods section. 
OVA-treated control mice were injected with control Ab at the same 
time points indicated. BAL fluid was obtained 3 h after OVA treat-
ment on day 21 and number of eosinophils was determined. Each cir-
cle represents a single control mouse (open circle) or a single test 
mouse (closed circle) analyzed. Bars represent the mean of each 
group. Significant difference between groups was determined using 
the Student’s t test (*P , 0.001).
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Chemokine expression during lung eosinophilia in lympho-
cyte deficient mice. To determine whether the absence of
eosinophilia in RAG-1 and CD4-deficient mice was related to
changes in the expression of eosinophilic chemokines such as
eotaxin, RANTES, and MIP-1a, Northern analyses were per-
formed using RNA from the lungs of these mutant mice at dif-
ferent time points after OVA treatment. Fig. 4 B shows that in
RAG-1 and CD4-deficient mice, which do not develop OVA-
Figure 4. Role of lympho-
cyte subsets in lung eosino-
philia and its correlation with 
chemokine mRNA expres-
sion. (A) OVA-induced leu-
kocyte accumulation in the 
BAL fluid of lymphocyte-
deficient mice. BAL fluid 
from CD3e transgenic mice 
and from RAG-1, CD4-, or 
CD8-deficient mice was ob-
tained 3 h after OVA admin-
istration on day 21 of OVA 
treatment. Numbers of (left) 
eosinophils, (middle) lym-
phocytes, and (right) mac-
rophages were calculated as 
the product of the total cellu-
larity of the BAL and the 
percentage of each cell
type. Data represent the 
mean6SEM for three repre-
sentative experiments with 
four mice in each group
(n 5 12). Numbers of infil-
trating eosinophils, lympho-
cytes, and macrophages in 
the BAL fluid of two differ-
ent control groups of mice 
(control group 1 “PBS”: 
PBS-treated C57BL/6J or wt 
129sv/C57BL/6J mice; con-
trol group 2 “1/1”: OVA-
treated wt 129sv/C57BL/6J 
mice) on day 21 is also 
shown. (B) Expression of the 
eosinophilic chemokines eo-
taxin, RANTES, and
MIP-1a mRNAs in the lung 
of lymphocyte-deficient mice 
during OVA treatment. 
Northern blot analysis was 
performed using total RNA 
(20 mg) extracted from lungs 
of RAG-1, CD4-, and CD8-
deficient mice, 3 h after 
OVA administration on days 
15, 18, and 21. Total RNA 
from the lungs of OVA-
treated wt mice at the same 
time points was used as a 
control. Expression of two 
representative wt mice out of 
five at each time point, two 
out of five immunodeficient 
mice on days 15 and 18, and 
three out of five immunode-
ficient mice on day 21 of treatment, is shown. Expression of b-actin was used to determine the quality and quantity of the RNA. (C) Expression 
of eotaxin protein in CD42/2 mice after OVA administration. Immunohistochemical staining was performed in frozen sections from OVA 
treated CD42/2 mice (II) or OVA-treated wt littermates (I) with anti-eotaxin mAb (mEOT-1). Eotaxin is clearly expressed within alveolar 
macrophages and alveolar epithelial cells in CD42/2 mice, although no infiltrating leukocytes were observed. 31,000
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Figure 5. ICAM-1 and VCAM-1 expression in the eosinophilic lung. Frozen sections of lungs from OVA-treated wt (middle row) or CD4-defi-
cient mice (bottom row) and of PBS-treated wt mice (top row) were stained with anti-ICAM-1 (middle column) or anti-VCAM-1 (right column) 
mAbs and then counterstained with hematoxylin. Pictures of lung sections from the same groups of mice stained with isotype-matched irrelevant 
control (left column) are included for comparison. Arrows indicate the position of airways and arrowheads of vessels. Bar, 50 mm.
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induced pulmonary eosinophilia, there was a significant level
of expression of eotaxin, RANTES, and MIP-1a (especially on
day 21 which coincides with maximal eosinophilia in wt mice).
The levels of expression of these chemokines in CD4 or RAG-
1–deficient mice were comparable to those found in OVA-
treated wt and CD8-deficient mice (Fig. 4 B). To evaluate par-
ity between chemokine mRNA expression and chemokine
protein production in the CD4-deficient mice, eotaxin protein
expression was examined in sections of lungs from OVA-
treated CD4-deficient mice. Even though there was no infiltra-
tion in the lungs from these mice there was at least as much, if
not more, eotaxin epression within sections, correlating with
the mRNA data (Fig. 4 C). An increase in the amount of eo-
taxin immunodetected on macrophages was noted (Fig. 4 C).
Experiments are underway to confirm this finding at the mo-
lecular level.
Adhesion receptor expression during lung eosinophilia in
lymphocyte-deficient mice. The mRNA expression of key
eosinophilic chemokines (eotaxin and RANTES) was virtually
unaffected in lymphocyte-deficient mice during the response
to OVA in vivo. Therefore, we examined changes in the ex-
pression of selected adhesion receptors involved in eosinophil
extravasation (11, 14) to determine whether suboptimal upreg-
ulation of adhesion receptor expression in lymphocyte-defi-
cient mice could account for the lack of eosinophil accumula-
tion observed in these mutant mice during the OVA treatment.
To this end we assesed the protein expression of ICAM-1 and
VCAM-1 genes by immunohistochemistry in frozen sections
of the lungs of CD4-deficient mice and wt mice after OVA
treatment on day 21 (3 h after challenge). Similar expression of
ICAM-1 is observed in wt and CD4-deficient mice in vascular
and alveolar endothelium (Fig. 5). In contrast, although strong
expression of VCAM-1 was observed in wt mice after OVA-
treatment (Fig. 5), it was only weakly expressed in vessels in
OVA-treated CD4-deficient mice and untreated wt mice (Fig.
5). PBS-treated mice showed minimal expression of both
ICAM-1 and VCAM-1 (Fig. 5).
Role of selected adhesion receptors in pulmonary eosino-
philia: response to OVA in adhesion receptor deficient mice.
The eosinophil–endothelial cell interactions required for ex-
travasation necessitates enhanced expression of endothelial
adhesion molecules and eosinophil surface integrins (11, 14).
From the results presented in the previous section and from
the work of others (16), we hypothesized that the expression of
VCAM-1 and ICAM-1 is critically regulated by T-lympho-
cyte–derived cytokines and is essential for the development of
lung eosinophilia. To test this hypothesis, we used ICAM-1–
deficient mice and VCAM-1–hypomorphic mutant mice to
evaluate the specific contribution of these adhesion receptors
to OVA-induced pulmonary eosinophilia. Since eosinophils
express P-selectin ligands and L-selectin, mice deficient for
these molecules were also used in these experiments. On day
21, 3 h after OVA administration, which correspond with max-
imum eosinophilia in wt mice, no eosinophil accumulation was
observed either in the BAL fluid (Fig. 6) or in lung tissue (data
not shown) of ICAM-1–deficient mice and VCAM-1–hypo-
morphic mutant mice. At the same time point, the total num-
ber of BAL lymphocytes in these mutant mice was reduced by
more than 65 and 85% in ICAM-1 and VCAM-1–mutant mice
respectively, compared to OVA-treated wt littermates (Fig. 6).
Analysis of eosinophil accumulation in L-selectin–deficient
mice in response to OVA showed that L-selectin is not essen-
tial for induction or maintenance of pulmonary eosinophilia.
No differences in the number of BAL eosinophils were found
in these mutant mice compared to control animals (Fig. 6).
When numbers of BAL lymphocytes were analyzed, L-selec-
tin–mutant mice showed an identical lymphocyte accumula-
tion to that observed in wt littermates (Fig. 6). The BAL fluid
of P-selectin–deficient mice showed only 20% of the eosino-
phil infiltration 3 h after the last OVA inhalation when com-
pared to wt littermates (Fig. 6). Interestingly, at the same time
Figure 6. Enumeration of leukocytes (eosinophils, lymphocytes, and 
macrophages) in the BAL fluid of different adhesion receptor defi-
cient mice in response to OVA. BAL fluid from ICAM-1, VCAM-1, 
L-selectin–, and P-selectin–mutant mice was obtained 3 (black bars) 
or 7 h (white bars) from different groups of mice after OVA adminis-
tration on day 21 of treatment. OVA-treated wt 129sv/C57BL/6J 
mice were used as control (1/1). Numbers of eosinophils (top), lym-
phocytes (middle), and macrophages (bottom) were calculated as the 
product of the total cellularity of the BAL and the percentage of each 
cell type. Figure shows mean6SEM for three individual experiments 
with 4 OVA-treated mice per time point and experiment with the ex-
ception of L-selectin–deficient mice (3 mice per time point) and 
VCAM-1–deficient mice. (ND, not analyzed at 7 h after OVA
treatment).
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point no reduction in the number of BAL lymphocytes was de-
tected (Fig. 6). When P-selectin–deficient mice were analyzed
7 h after the last OVA challenge, we detected a 2.5-fold in-
crease in the number of eosinophils in BAL fluid when com-
pared with the OVA-treated wt mice at the same time point
(Fig. 6). ICAM-1 and VCAM-1–mutant mice did not show any
increase in eosinophil infiltration by 7 h after last OVA admin-
istration (Fig. 6). No significant differences were found in mac-
rophage accumulation in the BAL fluid of the different mutant
mice and wt littermates after challenge with OVA (Fig. 6). The
lack of adhesion receptors may result in impaired eosinophil
differentiation. Therefore, deficient mice were injected intra-
venously with IL-5. No subsequent differences in the numbers
of circulating eosinophils were detected among these IL-5–
injected mutant and wt mice (data not shown).
Discussion
In this report we have used a mouse model of OVA-induced
pulmonary eosinophilia in vivo to demonstrate that (a) there is
a differential accumulation of leukocyte subtypes in the lung
during the response to OVA, consisting of an early accumula-
tion of infiltrating macrophages and a late increase of T-lym-
phocytes and eosinophils; (b) the mRNA expression of specific
chemokines (eotaxin, RANTES, and MCP-1/JE) parallels in-
filtration of lungs by these three leukocyte subtypes; (c) neu-
tralization of eotaxin in vivo with specific Ab reduces OVA-
induced lung eosinophilia by 50%; (d) mature CD41 T cells
are absolutely required for OVA-induced eosinophil migra-
tion and accumulation in the lung; (e) the presence of T cells is
not required for the expression of the eosinophilic chemokines
RANTES, MIP-1a, and eotaxin or for their proper regulation;
(f) the expression of RANTES and eotaxin is not sufficient to
induce eosinophil accumulation in the absence of CD41 T cells
in vivo; (g) the presence of CD41 T cells is critical for the
proper enhancement of VCAM-1, but not ICAM-1 expres-
sion, in the lung during OVA treatment; and (h) the absence
of ICAM-1 or VCAM-1 prevents the development of pulmo-
nary eosinophilia whereas expression of L-selectin and P-selec-
tin is not essential to achieve lung eosinophil accumulation in
vivo.
The accumulation of eosinophils and T-lymphocytes in the
lung is parallel, and is preceded by a transient accumulation of
macrophages. This differential accumulation correlates with a
distinct pattern of expression of specific chemokines. The re-
cruitment of leukocytes from the blood to sites of inflamma-
tion is strongly regulated in vivo by mechanisms that allow
selective leukocyte–endothelial cell recognition. These mecha-
nisms display total specificity in relation to the stimulus induc-
ing inflammation, cell response, and the tissue site involved.
Based on a murine model of lung eosinophilia induced by the
repeated exposure of mice to aerosolized OVA (23), we have
analyzed cell subtypes involved in eosinophilia. We describe
here that there is a macrophage accumulation at the early
stages of challenge and that T-lymphocytes parallel eosinophil
infiltration. Whereas eosinophils and T-lymphocytes were pre-
dominant on day 21 in both BAL and lung tissue, macrophages
were the most abundant leukocyte type on day 15 in the lungs
of OVA-treated mice (Fig. 1). These two events characterize
pulmonary eosinophilia in this model. No significant and or-
dered neutrophil or B cell accumulation was detected during
the course of OVA treatment (data not shown). Mast cells,
which have been described as participating in eosinophil-medi-
ated inflammatory reactions (69), are not significantly increased
during the development of this model of antigen-induced eosi-
nophilia (data not shown).
The presence of infiltrating macrophages in the lung during
the sensitization phase (day 8; data not shown) and early stage
of OVA challenge (Fig. 1) is consistent with the hypothesis
that these leukocytes play a prominent role in airway hyperre-
sponsiveness (8, 27). To dissect the specific role that macro-
phages might play in this model of OVA-induced eosinophilia,
we attempted to eliminate macrophages in vivo using the drug
dichloromethylene-diphosphonate (Cl2MDP) encapsulated in
liposomes (70). Although a clear reduction (60%) in BAL pul-
monary eosinophilia was detected in Cl2MDP-treated mice af-
ter OVA-challenge, these experiments were unsatisfactory
due to the incomplete depletion of macrophages and to possi-
ble secondary effects of the drug (data not shown). The study
of the role of macrophages in lung eosinophilia using a geneti-
cally “clean” system is hampered by the lack of availability of
macrophage deficient mice. Mice lacking M-CSF (op/op) or
GM-CSF expression or both, still have significant numbers of
alveolar macrophages (71, 72). Thus, although our preliminary
results suggest a participation of macrophages in the early
phases of lung eosinophilia, the final confirmation of these re-
sults awaits the development of better tools (macrophage-defi-
cient mice) to address this issue.
Interestingly, we found that MCP-1/JE expression corre-
lates with lung macrophage accumulation whereas the expres-
sion of RANTES and eotaxin is concomittant with lymphocyte
and eosinophil infiltration (Fig. 2 A). The expression pattern
of MIP-1a mRNA reflects that seen for eotaxin and RANTES
rather than the mRNA pattern observed for MCP-1/JE (Fig. 2
A). This result suggests that MIP-1a is playing a role in the re-
cruitment of eosinophils in our model and is in accordance
with the recent description of MIP-1a as an eosinophilic
chemokine (65). Taken together these findings indicate that
there is a differential expression of chemokines during OVA-
induced eosinophilia in vivo which directly correlates with the
arrival of specific leukocyte types in the lung.
Of the chemokines able to attract eosinophils, eotaxin ap-
pears to be one of the most efficient (20, 67). This has led us
and others to suggest that this chemokine might play a key role
in lung allergic eosinophilia. In fact, neutralization of eotaxin
at day 21 in our model demonstrated that this chemokine is re-
sponsible for the recruitment of approximately half of the eosi-
nophils that accumulate in the BAL fluid in response to aller-
gen challenge (Fig. 3). We are presently evaluating further the
specific contribution of eotaxin at different times of this aller-
gic response in the lung, as well as its overall contribution to
this process. Our results indicate that most of the infiltrating
leukocytes (eosinophils, lymphocytes, and monocytes) are not
producing eotaxin protein, at least at the time of maximal eosi-
nophilia (day 21, 3 h after OVA inhalation). We have previ-
ously reported that lymphocytes and monocytes can produce
eotaxin mRNA after activation in vitro (23). Similarly, Ponath
et al. reported that human eosinophils are able to produce eo-
taxin mRNA (67). However, at the point of maximal eosino-
philia in vivo, these three cell types do not overtly produce eo-
taxin protein. Rather, the principal cells producing eotaxin in
response to OVA in this model are resident lung cells (mainly
epithelial cells and alveolar macrophages with some possible
contribution from endothelial cells).
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The presence of CD41 T cells is essential for the develop-
ment of lung eosinophilia in vivo, but not for the expression of
eosinophilic chemokines. To evaluate the relevance of lym-
phocytes and of specific subpopulations in OVA-induced eosi-
nophil accumulation in the lung and the putative role that
these cells might play, we have used mice lacking specific lym-
phocyte subtypes. Here we demonstrate that there is no OVA-
induced eosinophil accumulation in the BAL fluid of RAG-1–
deficient mice (lacking T- and B-lymphocytes) (68) or CD3e
transgenic mice (lacking T and NK cells) (48) (Fig. 4 A). This
suggests that T cells are required for the induction of lung eosi-
nophilia and that B cells are not sufficient to induce this physi-
ological response. Since we did not detect any significant lym-
phocyte infiltration in CD3e transgenic mice, the OVA-induced
lymphocyte infiltrate must be composed predominantly of
T cells (Fig. 4 A). This was confirmed by stained lung sections
from OVA-treated mice with an anti-IgM mAb (data not
shown). Furthermore, the prevention of eosinophil accumula-
tion in BAL and lung tissue in CD41 T-lymphocyte–deficient,
but not in CD81 T-lymphocyte–deficient mice after OVA-
challenge (Figs. 4, 5, and data not shown) demonstrates that
CD41 T-lymphocytes are required for the induction and devel-
opment of lung eosinophilia.
A number of studies have showed that airway hyperre-
sponsiveness and pulmonary inflammation can be associated
with a Th2 pattern of cytokine expression (37, 73–76). As yet,
there has been no direct evidence that T-lymphocytes mediate
in vivo antigen-induced eosinophilia. As demonstrated using
SCID mice, airway hyperreactivity induction requires the pres-
ence of lymphocytes (75) but the association of airway hyper-
reactivity and pulmonary eosinophil infiltration is still not un-
derstood since neither IL-5 or eosinophils support airway
hyperreactivity in an in vivo murine model of pulmonary in-
flammation (75). Elegant and thorough studies have demon-
strated a key role for CD41 T cells in the development of tra-
cheal (77) or pulmonary (78) antigen-induced eosinophil
infiltration by mAb-depletion of CD41 T cells. However, a
critical role for CD81 T cells in the development of lung eosi-
nophilia and airway responsiveness has also been documented
in another model of airway sensitization in which priming by
intraperitoneal injection of OVA was omitted (79). Expression
of chemokines during CD41- or CD81 T cell–dependent eosi-
nophilia in these two different mouse models is currently being
investigated in our laboratory. These results illustrate that the
contribution of CD41 or CD81 T cells to eosinophil accumula-
tion is dependent upon the particular methods used to induce
allergic inflammation. In addition, the results obtained from all
these experiments are conditioned by the finding that human
eosinophils also express the CD4 receptor (14) and by possible
secondary effects mediated by the injection of mAbs in vivo.
In this study we use a “clean” genetic deficiency to demon-
strate that the absence of CD41 T-lymphocytes (but not CD81
T cells) abolishes pulmonary eosinophilia without affecting
eosinophil differentiation. On the other hand, in these immu-
nodeficient mice it is difficult to decide whether the interference
with the sensitization and/or with the induction phase of the
response to OVA results in the lack of eosinophil infiltration.
We are evaluating the OVA-induced immune response in lym-
phocyte-deficient mice as well as establishing the role that B
and T cells play in both the sensitization and challenge phases
by depletion of these particular lymphocyte subtypes at differ-
ent time points of the treatment. This will lead us to a better
characterization of both the sensitization and induction phases
of the response in our murine model of lung eosinophilia. An-
other possible explanation for the absence of eosinophilia in
CD4-deficient mice could be a decrease in the number of bone
marrow or peripheral blood eosinophils because of the CD4
deficiency. CD4-deficient mice and wt littermates were found
to have similar basal levels of eosinophils in peripheral blood
before treatment (data not shown). After OVA treatment, it is
possible that levels of peripheral blood eosinophils are lower
in CD4-deficient mice. We could not test this hypothesis di-
rectly by evaluating increases in peripheral blood eosinophils
in OVA-treated CD4-deficient mice because no such increase
is detected after treatment of wt mice in this model. Instead,
we took advantage of the fact that intravenous IL-5 induces a
rapid reduction in the number of eosinophils in bone marrow
due to their mobilization to the blood (43). We did not detect
any differences in the number of IL-5–mobilized circulating
eosinophils among these wt and mutant mice (not shown). In
addition, eosinophil accumulation in the peritoneum of CD4-
deficient mice after repeated peritoneal administration of IL-5
suggests that these leukocytes maintain their ability to extrava-
sate in vivo, at least to the peritoneum.
We hypothesized that CD41 lymphocytes might be essen-
tial for the development of lung eosinophilia because they pro-
duce or regulate the expression of eosinophilic chemokines or
because they regulate the upregulation/activation of critical
adhesion receptors used by eosinophils during their transmi-
gration in vivo. As shown above, the infiltrating cells in the
lung are not the main producers of at least one eosinophilic
chemokine, eotaxin (Fig. 2 B). Therefore, we would not expect
a reduction of eotaxin or RANTES expression in CD4-defi-
cient mice. However, CD41 T-lymphocytes can provide signals
that regulate the expression of these chemokines by epithelial
and endothelial cells. To test these possibilities, we studied the
RNA expression of eotaxin and RANTES in lymphocyte-defi-
cient mice.
The mRNA expression of chemokines able to induce eosi-
nophil recruitment (eotaxin, RANTES, and MIP-1a) after
OVA administration, is not influenced in lymphocyte-deficient
mice. In RAG-1 and CD4-deficient mice, that are resistant to
OVA-induced pulmonary eosinophilia, there exist significant
levels of eotaxin, RANTES, and MIP-1a expression when
compared with OVA-treated wt and CD8-deficient mice. This
finding was subsequently confirmed at the protein level for eo-
taxin. Based on these results, we can conclude that the expres-
sion of these chemokines alone is not sufficient to drive leuko-
cyte recruitment in vivo and, that CD41 T cells, which are
absolutely required for induction of eosinophilia, do not regu-
late the expression of these eosinophilic chemokines. Possible
candidates capable of regulating the expression of chemokines
in the lung of lymphocyte-deficient mice could be mast cells or
macrophages. On the other hand, the expression of these eosi-
nophilic chemokines in RAG-1–deficient mice or CD4-defi-
cient mice is not due to a non-specific response to large doses
of OVA or to the effect of some contaminant since we have re-
cently reported that the novel eosinophilic chemokine MCP-5
(80) is expressed in the lung of wt mice but not of RAG-1–
deficient mice after OVA treatment (80).
The expression of selected adhesion molecules is T-lym-
phocyte dependent. The expression of ICAM-1 and VCAM-1
is critical for the accumulation in vivo of eosinophils in the
lung. The process of eosinophil–endothelial cell interactions
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involves several adherence pathways (14). Eosinophils can
bind to ICAM-1 and to VCAM-1 by means of LFA-1 and
VLA-4, respectively. They also express L-selectin and ligands
for P-selectin (11, 12). We examined the expression of both
ICAM-1 and VCAM-1 proteins in our model of OVA-induced
eosinophilia in wt and CD4-deficient mice. While OVA-
treated wt and CD4-deficient mice exhibited similar staining
patterns of ICAM-1 protein expression in alveoli and blood
vessels (Fig. 5) a differential staining pattern was clearly ob-
served for VCAM-1, where increased vascular endothelial
staining was detected in OVA-treated wt, but not in CD4-defi-
cient mice (Fig. 5). This implies that adhesion molecules are
differentially modulated by CD41 T cells since we have shown
that VCAM-1, but not ICAM-1, is dramatically increased in
the presence, but not absence, of these cells, and that CD41 T
cells are not directly involved in the regulation of ICAM-1
protein expression.
We have examined the role that the adhesion receptors
ICAM-1, VCAM-1, P-selectin, and L-selectin play in OVA-
induced pulmonary eosinophilia by using mice lacking these
adhesion molecules. Our studies in vivo demonstrate that eosi-
nophil migration into the lung tissue (data not shown) and
BAL fluid (Fig. 6) is abolished in the absence of ICAM-1 and
VCAM-1. Previous in vivo blocking experiments have shown
that VCAM-1/VLA-4 interactions play a predominant role in
controlling antigen-induced eosinophil and T cell recruitment
into the mouse trachea but ICAM-1/LFA-1 interactions are
only critical in regulating T cell recruitment in the same model
of inflammation (16). Studies of eosinophil transmigration in
vitro have reported a 24% reduction in IL-1 or TNF-a–induced
eosinophil migration by using mAb against ICAM-1 while
the combination of anti–E-selectin, anti-VCAM-1, and anti-
ICAM-1 mAbs resulted in additive inhibition of transmigra-
tion (15). Our results indicate that OVA-induced eosinophil
accumulation in the lung requires interactions mediated by
ICAM-1 and VCAM-1 with their counter-receptors. In both
strains of adhesion receptor-deficient mice, no eosinophils
were detected in BAL fluid after OVA treatment (Fig. 6). Fur-
thermore, T cell infiltration is also affected in ICAM-1 and
VCAM-1–mutant mice. We found a 32 and 14% lymphocyte
accumulation in the BAL fluid of OVA-treated ICAM-1–defi-
cient mice and VCAM-1–hypomorphic mutant mice, respec-
tively, when compared with OVA-treated wt controls (Fig. 6).
Since CD41 T-lymphocytes are essential for the development
of pulmonary eosinophilia during OVA treatment, we can not
conclude from these experiments whether ICAM-1 and/or
VCAM-1 play a critical role in lung eosinophilia either by di-
rectly mediating eosinophil–endothelium interactions or by fa-
cilitating CD41 T cell activation and/or infiltration, or both ef-
fects together. Adoptive transfer experiments into deficient
mice are underway in our laboratory to address this question.
In contrast, the absence of L-selectin and P-selectin expres-
sion does not prevent the development of pulmonary eosino-
philia in this model. The number of BAL leukocyte subtypes
remained comparable in L-selectin–deficient mice and wt lit-
termates at the different time points analyzed (3 and 7 h) after
OVA administration on day 21 (Fig. 6). Three hours after
OVA challenge on the same day, P-selectin–deficient mice
have fewer eosinophils in the lung than wt mice. BAL fluid ob-
tained from these treated mice showed 20% of the eosinophil
accumulation observed in wt littermates without reduction in
the number of infiltrating lymphocytes (Fig. 6). Since lympho-
cyte migration remains unaffected, the reduced eosinophilia at
this time point might be directly attributable to the effect of
the P-selectin deficiency. However, the increase in the number
of eosinophils (2.5-fold over the control at this time point) in
the BAL fluid of OVA-treated P-selectin–deficient mice ob-
tained 7 h after OVA challenge, suggests that in the absence of
P-selectin–mediated interactions, eosinophil accumulation in
the lung is suboptimal and therefore delayed in vivo. However,
P-selectin is not essential for the development of eosinophilia
since in the absence of P-selectin expression, eosinophils and
endothelial cells use alternative adhesion pathways that allow
delayed eosinophil migration into the lung.
Numbers of macrophages (Fig. 6) and neutrophils (data
not shown) present in the BAL fluid of OVA-treated mutant
mice were also similar when compared with wt animals (data
not shown). The only exception was a 40% reduction in neu-
trophils in ICAM-1–deficient mice (not shown). This reduc-
tion was also detectable in these mutant mice even before
treatment and may be related to the fact that ICAM-1 is re-
quired for neutrophils to migrate into tissues (52).
The study of leukocytes and the molecules that they pro-
duce or upregulate during recruitment and accumulation of
specific leukocyte subsets into sites of inflammation, may lead
to the development of therapeutic approaches able to inhibit
the pathogenesis of allergic inflammation. Asthma is a com-
plex syndrome that involves recruitment of eosinophils and
their accumulation in the lung. Although murine models of
lung inflammation do not completely represent the complexity
of this syndrome, they may delineate particular pathways op-
erating within it. The results presented here using one particu-
lar murine model together with additional information yielded
from other, different, models of lung inflammation may con-
tribute to a better comprehension of the mechanisms impli-
cated in the establishment of eosinophilia within the inflamma-
tory lung.
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